Rubin Jonathan 4

What Happened

• Jonathan Rubin, Senior Vice President and Chief Medical Officer of Supernus Pharmaceuticals (SUPN), was granted two equity awards on Feb 18, 2026: 13,500 and 3,000 derivative units. Both awards were reported as acquired at $0.00, indicating granted awards (not open-market purchases). The awards total 16,500 units and will vest over time rather than converting immediately into tradable shares.

Key Details

• Transaction date: 2026-02-18; Form 4 filed: 2026-02-20 (timely filing under the two-business-day rule).
• Reported acquisition amounts/prices: 13,500 units @ $0.00 and 3,000 units @ $0.00 (awards/grants, no cash paid).
• Vesting: Awards vest in four equal annual installments beginning Feb 18, 2027 (footnotes reference a four-year vesting schedule).
• Award types: Footnotes indicate one award involves stock options (vesting in four equal annual installments) and the other comprises restricted stock units (RSUs) that convert to one share each upon vesting and are settled in common stock.
• Shares included in holdings: The filing notes an additional 269 shares acquired through the issuer’s Employee Stock Purchase Plan (ESPP).
• Shares owned after transaction: Not specified in the excerpt provided.
• Filing timeliness: Filed promptly (not marked late).

Context

• These were grants (A = award/other acquisition). The awards are derivative and subject to multi-year vesting, so they do not represent immediate sales or purchases of tradable shares. RSUs convert to common stock only as they vest; options (if applicable) will require exercise according to their terms. Grants like these are routine compensation for executives and do not by themselves indicate a near-term market action.